A multicenter, retrospective, cohort study evaluating safety and efficacy of Romiplostim and Eltrombopag in systemic lupus erythematosus associated immune thrombocytopenia.

Trial Profile

A multicenter, retrospective, cohort study evaluating safety and efficacy of Romiplostim and Eltrombopag in systemic lupus erythematosus associated immune thrombocytopenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Eltrombopag (Primary) ; Romiplostim (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jan 2017 New trial record.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top